(19)
(11) EP 3 468 611 A1

(12)

(43) Date of publication:
17.04.2019 Bulletin 2019/16

(21) Application number: 16831758.4

(22) Date of filing: 29.12.2016
(51) International Patent Classification (IPC): 
A61K 47/64(2017.01)
C07K 14/50(2006.01)
 A61K 47/60(2017.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/IB2016/058083
(87) International publication number:
WO 2017/216620 (21.12.2017 Gazette 2017/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 13.06.2016 PL 41754416

(71) Applicant: Uniwersytet Wroclawski
50-137 Wroclaw (PL)

(72) Inventors:
  • KRZYsCIK, Mateusz
    58-506 Jelenia Góra (PL)
  • LOBOCKI, Michal
    58-560 Jelenia Góra (PL)
  • SOKOLOWSKA-WeDZINA, Aleksandra
    56-416 Twardogóra (PL)
  • WIDERSKA, Karolina
    55-095 Dlugoleka (PL)
  • JAKIMOWICZ, Piotr
    53-149 Wroclaw (PL)
  • ZAKRZEWSKA, Malgorzata
    50-369 Wroclaw (PL)
  • KROWARSCH, Daniel
    50-142 Wroclaw (PL)
  • OTLEWSKI, Jacek
    53-149 Wroclaw (PL)

(74) Representative: Witek, Rafal 
WTS Patent Attorneys Witek, Sniezko & Partners ul. Weigla 12
53-114 Wroclaw
53-114 Wroclaw (PL)

   


(54) HUMAN FIBROBLAST GROWTH FACTOR 2 (FGF2) - CYTOTOXIC DRUG CONJUGATES FOR TARGETED THERAPY OF FGFR-RELATED CANCERS